Real-world experience with elranatamab is reinforcing and extending the efficacy and safety profile seen in clinical trials. Data from large real-world cohorts show that most patients initiating elranatamab are heavily pretreated and triple-class exposed, with approximately 20% having received prior BCMA-directed therapy, including CAR-T and antibody-drug conjugates . 1 Notably, elranatamab is being used effectively in populations frequently excluded from pivotal trials, including patients with renal disease, congestive heart failure, concurrent amyloidosis, extramedullary disease, and plasma cell leukemia.

In these real-world cohorts, 12- and 18-month progression-free survival reached 57–66%, outcomes considered unprecedented for this heavily pretreated population prior to the immunotherapy era. 1 Emerging evidence also supports use in patients with severe renal impairment, including…